Neurocognitive Disorders Drug Reference Chart Assignment: Cholinesterase Inhibitors and Brexpiprazole for Alzheimer’s Dementia Care
Pharmacology students in psychiatric nursing programs seeking reliable guidance for their neurocognitive disorders assignment discover that completing a detailed drug reference chart on cholinesterase inhibitors and brexpiprazole ensures they understand essential clinical details for Alzheimer’s dementia treatment.
Complete attached Drug Reference Chart for each of the below treatments for neurocognitive disorders. Many learners report that organizing information this way helps them retain key facts for patient education and medication reconciliation in real-world settings.
Complete all required information listed in the chart for the medications provided below. Faculty members emphasize how this exercise mirrors the quick-reference tools used in busy clinics.
A. Cholinesterase inhibitors: Rivastigmine, Galantamine, and Donepezil B. FDA Approved for agitation associated with dementia due to Alzheimer’s: Rexulti (brexpiprazole)
Medication (Generic/Brand) FDA Indication(s)
Mechanism of Action Common Side effects Adverse Effects Required Tests/Labs Precaution/ Contraindications Dosage Range/Dosage forms In-text Citation
EXAMPLE: Fluvoxamine OCD Social Anxiety Disorder Blocks serotonin Reuptake pump -weight gain -sedation -sexual dysfunction -GI -Induce Mania (Bipolar) -suicidality under 24yrs old -Seizure -cbc -cmp -lipid -EKG -BMI, WT, VS Renal impairment Hepatic impairment Cardiac impairment Elderly Oral: 100-300mg (Stahl, 2024).
Recent meta-analyses from 2024 remind students that these agents show modest but measurable cognitive gains, so accurate chart entries support evidence-based decisions during clinical rotations. Learners may notice variations in dosing forms that affect adherence in older adults with swallowing difficulties.
Sample Response and Discussion Example
Students often start their chart by noting that donepezil remains the most widely prescribed cholinesterase inhibitor due to its once-daily dosing convenience. Recent meta-analyses confirm modest cognitive benefits across these agents while highlighting the need for careful monitoring of gastrointestinal side effects. When adding brexpiprazole the focus shifts to its unique role in agitation management supported by phase 3 trials that demonstrated statistically significant improvements on the Cohen-Mansfield Agitation Inventory scale. Practitioners appreciate how the chart format allows quick comparison of contraindications such as cardiac risks with cholinesterase inhibitors versus metabolic monitoring for brexpiprazole. Overall completing this task prepares learners to contribute confidently during multidisciplinary rounds. (Gao et al., 2024) https://doi.org/10.17219/acem/176051.
Evidence from large-scale reviews indicates that cholinesterase inhibitors can slow cognitive decline modestly in Alzheimer’s patients although individual responses vary considerably. Clinicians must weigh these benefits against potential adverse events when selecting therapy for older adults. Long-term data also suggest reduced mortality risk with consistent use of these agents a finding that underscores their value in comprehensive dementia care plans. Such insights come directly from recent umbrella reviews and randomized trials published in high-impact journals and help students connect classroom charts to actual patient outcomes in dementia units.
References
Gao, Y. et al. (2024) ‘Safety and efficacy of acetylcholinesterase inhibitors for Alzheimer’s disease: A systematic review and meta-analysis’, Advances in Clinical and Experimental Medicine, 33(11), pp. 1179-1187. doi:10.17219/acem/176051.
Moreta, M.P.G. et al. (2021) ‘Efficacy of Acetylcholinesterase Inhibitors on Cognitive Function in Alzheimer’s Disease. Review of Reviews’, Biomedicines, 9(11), p. 1689. doi:10.3390/biomedicines9111689.
Lee, D. et al. (2023) ‘Brexpiprazole for the Treatment of Agitation in Alzheimer Dementia: A Randomized Clinical Trial’, JAMA Neurology, 80(12), pp. 1307-1316. doi:10.1001/jamaneurol.2023.3810.
Aga, V.M. (2025) ‘Brexpiprazole for the Treatment of Agitation in Alzheimer’s Disease Dementia: Clinical Uncertainties and the Path Forward’, The American Journal of Geriatric Psychiatry, 33(3), pp. 322-329. doi:10.1016/j.jagp.2024.11.003.
